The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells.
Mendez S, Traslavina R, Hinchman M, Huang L, Green P, Cynamon MH, Welch JT. The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob Agents Chemother. 2009 Dec; 53(12):5114-21.